Myocardial fibrosis in congenital and pediatric heart disease

Area of Science:

• Cardiovascular Biology
• Pathology
• Medical Research

Background:

• Cardiac fibrosis is a prevalent condition in heart diseases like ischemic heart disease, inherited cardiomyopathies, diabetes, and aging.
• It is characterized by the excessive accumulation of extracellular matrix (ECM), which negatively impacts cardiac function.
• Four types of cardiac fibrosis exist: reactive interstitial, replacement, infiltrative interstitial, and endomyocardial fibrosis.

Purpose of the Study:

• To review the mechanisms underlying cardiac fibrosis, including fibroblast activation and myofibroblast differentiation.
• To discuss diagnostic techniques for assessing myocardial fibrosis.
• To explore potential therapeutic targets within fibrotic pathways.

Main Methods:

• Literature review of cardiac fibrosis mechanisms, diagnosis, and therapeutic targets.
• Analysis of the role of cardiac fibroblasts and myofibroblasts in ECM production.
• Examination of diagnostic modalities such as stress echocardiography, cardiac MRI, and PET.

Main Results:

• Cardiac fibrosis involves the activation of cardiac fibroblasts into myofibroblasts, leading to increased ECM deposition.
• Myofibroblasts express specific markers like smooth muscle α-actin, SM22, and caldesmon.
• Key pathways implicated in cardiac fibrosis include the renin-angiotensin-II-aldosterone system, TGF-β signaling, and activin-linked kinase 5.

Conclusions:

• Cardiac fibrosis is a significant contributor to morbidity and mortality in heart disease.
• Diagnostic tools like stress echocardiography, cardiac MRI, and PET are crucial for assessment.
• While pathways like TGF-β signaling present therapeutic targets, their broad physiological roles necessitate cautious intervention.